Symbols / MIRM
MIRM Chart
About
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.44B |
| Enterprise Value | 5.47B | Income | -41.42M | Sales | 471.79M |
| Book/sh | 5.69 | Cash/sh | 7.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | 355 | IPO | — |
| P/E | — | Forward P/E | 2773.68 | PEG | — |
| P/S | 13.64 | P/B | 18.89 | P/C | — |
| EV/EBITDA | -311.24 | EV/Sales | 11.59 | Quick Ratio | 3.01 |
| Current Ratio | 3.31 | Debt/Eq | 109.15 | LT Debt/Eq | — |
| EPS (ttm) | -0.84 | EPS next Y | 0.04 | EPS Growth | — |
| Revenue Growth | 47.20% | Earnings | 2026-02-25 | ROA | -3.60% |
| ROE | -15.81% | ROIC | — | Gross Margin | 79.92% |
| Oper. Margin | 1.96% | Profit Margin | -8.78% | Shs Outstand | 59.88M |
| Shs Float | 44.69M | Short Float | 13.02% | Short Ratio | 9.38 |
| Short Interest | — | 52W High | 109.28 | 52W Low | 36.88 |
| Beta | 0.50 | Avg Volume | 757.34K | Volume | 613.46K |
| Target Price | $117.45 | Recom | Strong_buy | Prev Close | $105.89 |
| Price | $107.48 | Change | 1.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$117.45
Mean price target
2. Current target
$107.48
Latest analyst target
3. DCF / Fair value
$14.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$107.48
Low
$95.00
High
$140.00
Mean
$117.45
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | init | RBC Capital | — → Outperform | $130 |
| 2026-01-30 | main | Morgan Stanley | Overweight → Overweight | $123 |
| 2026-01-26 | main | HC Wainwright & Co. | Buy → Buy | $130 |
| 2026-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-12-19 | main | Citizens | Market Outperform → Market Outperform | $140 |
| 2025-12-16 | main | Stifel | Buy → Buy | $98 |
| 2025-12-09 | main | Morgan Stanley | Overweight → Overweight | $95 |
| 2025-12-09 | main | Baird | Outperform → Outperform | $88 |
| 2025-12-09 | main | Evercore ISI Group | Outperform → Outperform | $94 |
| 2025-12-08 | main | Cantor Fitzgerald | Overweight → Overweight | $130 |
| 2025-11-05 | main | Cantor Fitzgerald | Overweight → Overweight | $95 |
| 2025-11-05 | main | Citizens | Market Outperform → Market Outperform | $95 |
| 2025-11-05 | main | HC Wainwright & Co. | Buy → Buy | $81 |
| 2025-10-16 | main | Morgan Stanley | Overweight → Overweight | $81 |
| 2025-09-24 | init | TD Cowen | — → Buy | $95 |
| 2025-09-12 | main | JP Morgan | Overweight → Overweight | $77 |
| 2025-08-08 | main | Evercore ISI Group | Outperform → Outperform | $89 |
| 2025-08-07 | main | JMP Securities | Market Outperform → Market Outperform | $81 |
| 2025-08-07 | main | Raymond James | Strong Buy → Strong Buy | $82 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $80 |
- Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its 115% One-Year Surge? - Yahoo Finance Wed, 25 Feb 2026 01
- Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After A 108% One Year Rally? - simplywall.st ue, 24 Feb 2026 17
- Rare disease company Mirum lines up March investor talks online - Stock Titan Mon, 23 Feb 2026 21
- Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings - Benzinga ue, 24 Feb 2026 17
- RBC Capital Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation - Nasdaq Wed, 18 Feb 2026 20
- Howe Jolanda, SVP at Mirum Pharmaceuticals, sells $99997 in Mirm stock - Investing.com ue, 03 Feb 2026 08
- Drugmaker Mirum sets Feb. 25 call on 2025 results - Stock Titan Wed, 18 Feb 2026 21
- Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance Wed, 18 Feb 2026 15
- Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects - simplywall.st hu, 19 Feb 2026 11
- New Mirum staff get stock grants, some tied to 2027–28 net sales - Stock Titan ue, 10 Feb 2026 08
- Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum - Yahoo Finance ue, 13 Jan 2026 08
- Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback - Yahoo Finance hu, 11 Dec 2025 08
- Severe childhood liver itch gets new option as Canada authorizes LIVMARLI - Stock Titan hu, 05 Feb 2026 08
- How Investors Are Reacting To Mirum Pharmaceuticals (MIRM) Securing Health Canada PFIC Nod For LIVMARLI - simplywall.st ue, 10 Feb 2026 08
- MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance hu, 07 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2000 | 204180.0 | — | Sale at price 102.09 per share. | RAMASASTRY SAIRA | Director | — | 2026-02-13 00:00:00 | D |
| 1 | 2000 | 47020.0 | — | Conversion of Exercise of derivative security at price 23.51 per share. | RAMASASTRY SAIRA | Director | — | 2026-02-13 00:00:00 | D |
| 2 | 968 | 99998.0 | — | Sale at price 103.30 per share. | HOWE JOLANDA MARIE | Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 9108 | 940888.0 | — | Sale at price 103.30 per share. | PEETZ CHRISTOPHER | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 2631 | 271792.0 | — | Sale at price 103.30 per share. | RADOVICH PETER | President | — | 2026-02-02 00:00:00 | D |
| 5 | 1771 | nan | — | — | HOWE JOLANDA MARIE | Officer | — | 2026-01-30 00:00:00 | D |
| 6 | 842 | 80994.0 | — | Sale at price 96.19 per share. | HOWE JOLANDA MARIE | Officer | — | 2026-01-26 00:00:00 | D |
| 7 | 1053 | 101290.0 | — | Sale at price 96.19 per share. | BJERKHOLT ERIC H | Chief Financial Officer | — | 2026-01-26 00:00:00 | D |
| 8 | 6831 | 657088.0 | — | Sale at price 96.19 per share. | PEETZ CHRISTOPHER | Chief Executive Officer | — | 2026-01-26 00:00:00 | D |
| 9 | 3143 | 302331.0 | — | Sale at price 96.19 per share. | RADOVICH PETER | President | — | 2026-01-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -10.31M | 40.86K | -197.64K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.05 | 0.27 |
| NormalizedEBITDA | -48.97M | -87.41M | -123.76M | -65.03M |
| TotalUnusualItems | 0.00 | -49.08M | 906.00K | -732.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -49.08M | 906.00K | -732.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -87.94M | -163.41M | -135.66M | -83.99M |
| ReconciledDepreciation | 23.63M | 10.83M | 3.24M | 595.00K |
| ReconciledCostOfRevenue | 81.64M | 47.04M | 12.37M | 1.90M |
| EBITDA | -48.97M | -136.49M | -122.85M | -65.77M |
| EBIT | -72.60M | -147.32M | -126.09M | -66.36M |
| NetInterestIncome | -519.00K | -1.37M | -12.12M | -17.22M |
| InterestExpense | 14.31M | 15.11M | 15.98M | 17.59M |
| InterestIncome | 13.79M | 13.73M | 3.86M | 366.00K |
| NormalizedIncome | -87.94M | -124.64M | -136.53M | -83.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -87.94M | -163.41M | -135.66M | -83.99M |
| TotalExpenses | 424.49M | 295.53M | 208.28M | 192.55M |
| TotalOperatingIncomeAsReported | -87.61M | -109.15M | -131.22M | -173.41M |
| DilutedAverageShares | 47.52M | 40.89M | 33.98M | 30.32M |
| BasicAverageShares | 47.52M | 40.89M | 33.84M | 30.32M |
| DilutedEPS | -1.85 | -3.94 | -4.02 | -2.77 |
| BasicEPS | -1.85 | -3.94 | -4.01 | -2.77 |
| DilutedNIAvailtoComStockholders | -87.94M | -163.41M | -136.58M | -83.99M |
| AverageDilutionEarnings | 0.00 | 0.00 | -914.00K | 0.00 |
| NetIncomeCommonStockholders | -87.94M | -163.41M | -135.66M | -83.99M |
| NetIncome | -87.94M | -163.41M | -135.66M | -83.99M |
| NetIncomeIncludingNoncontrollingInterests | -87.94M | -163.41M | -135.66M | -83.99M |
| NetIncomeContinuousOperations | -87.94M | -163.41M | -135.66M | -83.99M |
| TaxProvision | 1.03M | 991.00K | -6.41M | 37.00K |
| PretaxIncome | -86.91M | -162.42M | -142.07M | -83.95M |
| OtherIncomeExpense | 1.21M | -51.90M | 1.27M | 106.69M |
| OtherNonOperatingIncomeExpenses | 1.21M | -2.82M | 365.00K | 107.42M |
| SpecialIncomeCharges | 0.00 | -49.08M | 0.00 | 0.00 |
| OtherSpecialCharges | 49.08M | |||
| GainOnSaleOfSecurity | 906.00K | -732.00K | ||
| NetNonOperatingInterestIncomeExpense | -519.00K | -1.37M | -12.12M | -17.22M |
| InterestExpenseNonOperating | 14.31M | 15.11M | 15.98M | 17.59M |
| InterestIncomeNonOperating | 13.79M | 13.73M | 3.86M | 366.00K |
| OperatingIncome | -87.61M | -109.15M | -131.22M | -173.41M |
| OperatingExpense | 342.85M | 248.49M | 195.91M | 190.65M |
| ResearchAndDevelopment | 140.63M | 102.61M | 106.84M | 131.43M |
| SellingGeneralAndAdministration | 202.22M | 145.88M | 89.07M | 59.22M |
| GrossProfit | 255.25M | 139.34M | 64.69M | 17.23M |
| CostOfRevenue | 81.64M | 47.04M | 12.37M | 1.90M |
| TotalRevenue | 336.89M | 186.37M | 77.06M | 19.14M |
| OperatingRevenue | 336.89M | 186.37M | 77.06M | 19.14M |
| Line Item | 2021-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 122.46K | |||
| OrdinarySharesNumber | 48.34M | 46.72M | 36.96M | 30.58M |
| ShareIssued | 48.34M | 46.72M | 36.96M | 30.71M |
| NetDebt | 85.58M | 20.09M | ||
| TotalDebt | 317.76M | 308.14M | 2.19M | 2.61M |
| TangibleBookValue | -24.18M | -4.25M | 83.08M | 101.47M |
| InvestedCapital | 533.72M | 555.09M | 142.04M | 120.21M |
| WorkingCapital | 266.24M | 300.48M | 125.50M | 124.00M |
| NetTangibleAssets | -24.18M | -4.25M | 83.08M | 101.47M |
| CapitalLeaseObligations | 9.68M | 1.72M | 2.19M | 2.61M |
| CommonStockEquity | 225.64M | 248.67M | 142.04M | 120.21M |
| TotalCapitalization | 533.72M | 555.09M | 142.04M | 120.21M |
| TotalEquityGrossMinorityInterest | 225.64M | 248.67M | 142.04M | 120.21M |
| StockholdersEquity | 225.64M | 248.67M | 142.04M | 120.21M |
| GainsLossesNotAffectingRetainedEarnings | -373.00K | 1.64M | -217.00K | -35.00K |
| OtherEquityAdjustments | -373.00K | 1.64M | -217.00K | -35.00K |
| RetainedEarnings | -644.18M | -556.24M | -392.82M | -257.16M |
| AdditionalPaidInCapital | 870.19M | 803.26M | 535.07M | 377.40M |
| CapitalStock | 5.00K | 5.00K | 4.00K | 3.00K |
| CommonStock | 5.00K | 5.00K | 4.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 445.11M | 397.95M | 210.87M | 174.44M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 318.56M | 310.89M | 146.14M | 131.84M |
| OtherNonCurrentLiabilities | 2.51M | 3.85M | 4.53M | 17.00K |
| NonCurrentDeferredLiabilities | 0.00 | 140.35M | 129.92M | |
| NonCurrentDeferredRevenue | 0.00 | 140.35M | 129.92M | |
| LongTermDebtAndCapitalLeaseObligation | 316.05M | 307.04M | 1.26M | 1.90M |
| LongTermCapitalLeaseObligation | 7.97M | 617.00K | 1.26M | 1.90M |
| LongTermDebt | 308.08M | 306.42M | ||
| CurrentLiabilities | 126.55M | 87.06M | 64.73M | 42.60M |
| OtherCurrentLiabilities | 1.09M | 2.00M | ||
| CurrentDebtAndCapitalLeaseObligation | 1.71M | 1.10M | 931.00K | 711.00K |
| CurrentCapitalLeaseObligation | 1.71M | 1.10M | 931.00K | 711.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 32.25M | 20.94M | 14.66M | 9.99M |
| PayablesAndAccruedExpenses | 92.59M | 65.02M | 48.05M | 29.90M |
| CurrentAccruedExpenses | 68.61M | 50.89M | 36.90M | 20.12M |
| InterestPayable | 2.11M | 2.11M | 0.00 | |
| Payables | 23.98M | 14.13M | 11.15M | 9.78M |
| OtherPayable | 9.36M | 6.72M | 2.46M | 610.00K |
| AccountsPayable | 14.62M | 7.42M | 8.69M | 9.17M |
| TotalAssets | 670.75M | 646.62M | 352.91M | 294.65M |
| TotalNonCurrentAssets | 277.97M | 259.08M | 162.68M | 128.06M |
| OtherNonCurrentAssets | 5.81M | 4.17M | 101.38M | 101.79M |
| InvestmentsAndAdvances | 12.53M | 0.00 | 0.00 | 4.98M |
| GoodwillAndOtherIntangibleAssets | 249.82M | 252.93M | 58.95M | 18.74M |
| OtherIntangibleAssets | 249.82M | 252.93M | 58.95M | 18.74M |
| NetPPE | 9.81M | 1.99M | 2.35M | 2.55M |
| GrossPPE | 9.81M | 1.99M | 2.35M | 2.55M |
| OtherProperties | 9.81M | 1.99M | 914.00K | 981.00K |
| BuildingsAndImprovements | 1.28M | 1.43M | 1.57M | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 392.79M | 387.54M | 190.22M | 166.59M |
| OtherCurrentAssets | 11.78M | 10.94M | 8.95M | 5.27M |
| PrepaidAssets | 5.27M | |||
| Inventory | 22.40M | 22.31M | 5.57M | 1.51M |
| FinishedGoods | 3.28M | 9.44M | 214.00K | 87.00K |
| WorkInProcess | 16.09M | 9.87M | 5.35M | 570.00K |
| RawMaterials | 3.03M | 3.00M | 0.00 | 856.00K |
| Receivables | 78.29M | 67.97M | 23.99M | 3.27M |
| AccountsReceivable | 78.29M | 67.97M | 23.99M | 3.27M |
| CashCashEquivalentsAndShortTermInvestments | 280.31M | 286.33M | 151.72M | 156.54M |
| OtherShortTermInvestments | 57.81M | 0.00 | 123.72M | 125.20M |
| CashAndCashEquivalents | 222.50M | 286.33M | 28.00M | 31.34M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.67M | -91.05M | -120.41M | -151.78M |
| IssuanceOfDebt | 0.00 | 305.30M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 216.68M | 107.37M | 6.91M |
| CapitalExpenditure | -20.99M | -20.11M | -278.00K | -19.02M |
| InterestPaidSupplementalData | 12.65M | 6.82M | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 1.00M | 125.00K | 0.00 | 0.00 |
| EndCashPosition | 222.93M | 286.33M | 128.00M | 131.34M |
| BeginningCashPosition | 286.33M | 128.00M | 131.34M | 142.09M |
| EffectOfExchangeRateChanges | -1.30M | -133.00K | 12.00K | -1.00K |
| ChangesInCash | -62.10M | 158.46M | -3.35M | -10.74M |
| FinancingCashFlow | 17.70M | 336.60M | 109.09M | 73.47M |
| CashFlowFromContinuingFinancingActivities | 17.70M | 336.60M | 109.09M | 73.47M |
| NetOtherFinancingCharges | -195.86M | -5.55M | 64.45M | |
| InterestPaidCFF | -121.00K | |||
| ProceedsFromStockOptionExercised | 17.70M | 10.47M | 7.27M | 2.10M |
| CashDividendsPaid | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 216.68M | 107.37M | 6.91M |
| CommonStockIssuance | 0.00 | 216.68M | 107.37M | 6.91M |
| NetIssuancePaymentsOfDebt | 0.00 | 305.30M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 305.30M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 305.30M | 0.00 | 0.00 |
| InvestingCashFlow | -90.12M | -107.20M | 7.70M | 48.55M |
| CashFlowFromContinuingInvestingActivities | -90.12M | -107.20M | 7.70M | 48.55M |
| NetOtherInvestingChanges | 108.00M | |||
| NetInvestmentPurchaseAndSale | -69.13M | 125.67M | 7.98M | -40.43M |
| SaleOfInvestment | 19.89M | 153.00M | 140.30M | 157.60M |
| PurchaseOfInvestment | -89.03M | -27.33M | -132.32M | -198.03M |
| NetBusinessPurchaseAndSale | 0.00 | -212.76M | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -212.76M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | -20.00M | -20.00M | 0.00 | -19.00M |
| PurchaseOfIntangibles | -20.00M | -20.00M | 0.00 | -19.00M |
| NetPPEPurchaseAndSale | -993.00K | -109.00K | -278.00K | -24.00K |
| PurchaseOfPPE | -993.00K | -109.00K | -278.00K | -24.00K |
| OperatingCashFlow | 10.32M | -70.94M | -120.14M | -132.76M |
| CashFlowFromContinuingOperatingActivities | 10.32M | -70.94M | -120.14M | -132.76M |
| ChangeInWorkingCapital | 22.59M | -19.22M | -21.05M | 16.98M |
| ChangeInOtherCurrentLiabilities | -782.00K | -940.00K | -711.00K | -649.00K |
| ChangeInOtherCurrentAssets | -1.50M | -511.00K | -127.00K | -519.00K |
| ChangeInPayablesAndAccruedExpense | 40.31M | 30.78M | 7.64M | 22.66M |
| ChangeInPayable | 40.31M | 30.78M | 7.64M | 22.66M |
| ChangeInAccountPayable | 40.31M | 30.78M | 7.64M | 22.66M |
| ChangeInPrepaidAssets | -849.00K | -3.60M | -3.68M | -4.01M |
| ChangeInInventory | -3.17M | -974.00K | -3.45M | -495.00K |
| ChangeInReceivables | -11.43M | -43.97M | -20.73M | 0.00 |
| ChangesInAccountReceivables | -11.43M | -43.97M | -20.73M | 0.00 |
| OtherNonCashItems | 2.22M | 54.82M | 12.91M | -90.03M |
| StockBasedCompensation | 48.44M | 35.02M | 27.01M | 23.09M |
| ProvisionandWriteOffofAssets | 2.61M | 9.26M | 0.00 | 0.00 |
| AmortizationOfSecurities | -1.73M | -1.70M | -137.00K | |
| DeferredTax | 0.00 | 0.00 | -6.58M | 0.00 |
| DeferredIncomeTax | 0.00 | 0.00 | -6.58M | 0.00 |
| DepreciationAmortizationDepletion | 23.63M | 10.83M | 3.24M | 595.00K |
| DepreciationAndAmortization | 23.63M | 10.83M | 3.24M | 595.00K |
| Depreciation | 3.68M | 975.00K | ||
| OperatingGainsLosses | -1.23M | 1.76M | -906.00K | 732.00K |
| GainLossOnInvestmentSecurities | -906.00K | 732.00K | ||
| NetForeignCurrencyExchangeGainLoss | -1.23M | 1.76M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -87.94M | -163.41M | -135.66M | -83.99M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MIRM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|